Promoting oligodendroglial-oriented differentiation of glioma stem cell: a repurposing of quetiapine for the treatment of malignant glioma

Yun Wang; Nanxin Huang; Hongli Li; Shubao Liu; Xianjun Chen; Shichang Yu; Nan Wu; Xiu-Wu Bian; Hai-Ying Shen; Chengren Li; Lan Xiao

doi:10.18632/oncotarget.16400

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Promoting oligodendroglial-oriented differentiation of glioma stem cell: a repurposing of quetiapine for the treatment of malignant glioma

Yun Wang, Nanxin Huang, Hongli Li, Shubao Liu, Xianjun Chen, Shichang Yu, Nan Wu, Xiu-Wu Bian, Hai-Ying Shen, Chengren Li _ and Lan Xiao

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:37511-37524. https://doi.org/10.18632/oncotarget.16400

Metrics: PDF 1949 views | HTML 3128 views | ?

Abstract

Yun Wang1,*, Nanxin Huang1,*, Hongli Li1, Shubao Liu1, Xianjun Chen1, Shichang Yu2, Nan Wu3, Xiu-Wu Bian2, Hai-Ying Shen4,*, Chengren Li1 and Lan Xiao1,*

1Department of Histology and Embryology, Chongqing Key Laboratory of Neurobiology, Third Military Medical University, Chongqing 400038, China

2Department of Pathology, Southwest Hospital, Chongqing 400038, China

3Department of Neurosurgery, Southwest Hospital, Chongqing 400038, China

4Robert Stone Dow Neurobiology Laboratories, Legacy Research Institute, Portland, OR 97232, USA

*These authors have contributed equally to this work

Correspondence to:

Chengren Li, email: [email protected]

Lan Xiao, email: [email protected]

Keywords: quetiapine, glioma stem cell, proliferation, differentiation, Wnt/β-catenin signaling pathway

Received: November 02, 2016 Accepted: March 01, 2017 Published: March 21, 2017

ABSTRACT

As a major contributor of chemotherapy resistance and malignant recurrence, glioma stem cells (GSCs) have been proposed as a target for the treatment of gliomas. To evaluate the therapeutic potential of quetiapine (QUE), an atypical antipsychotic, for the treatment of malignant glioma, we established mouse models with GSCs-initiated orthotopic xenograft gliomas and subcutaneous xenograft tumors, using GSCs purified from glioblastoma cell line GL261. We investigated antitumor effects of QUE on xenograft gliomas and its underlying mechanisms on GSCs. Our data demonstrated that (i) QUE monotherapy can effectively suppress GSCs-initiated tumor growth; (ii) QUE has synergistic effects with temozolomide (TMZ) on glioma suppression, and importantly, QUE can effectively suppress TMZ-resistant (or -escaped) tumors generated from GSCs; (iii) mechanistically, the anti-glioma effect of QUE was due to its actions of promoting the differentiation of GSCs into oligodendrocyte (OL)-like cells and its inhibitory effect on the Wnt/β-catenin signaling pathway. Together, our findings suggest an effective approach for anti-gliomagenic treatment via targeting OL-oriented differentiation of GSCs. This also opens a door for repurposing QUE, an FDA approved drug, for the treatment of malignant glioma.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16400

Publication Alerts

Research Papers:

Promoting oligodendroglial-oriented differentiation of glioma stem cell: a repurposing of quetiapine for the treatment of malignant glioma

Abstract